The authors and the publisher regret that a reference was omitted from the above article. The fourth sentence of the opening paragraph should read as follows
The compound PF-06372865, the subject of a study by van Amerongen and colleagues1 in a recent issue of the British Journal of Anaesthesia, was developed by Pfizer Inc (Cambridge, UK) as a partial agonist at the benzodiazepine binding sites of receptors containing α2, α3, or α5 subunits.2
Reference 1 and 2, as cited in this sentence, should have been listed as:
1. van Amerongen G, Siebenga PS, Gurrell R, et al. Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans. Br J Anaesth 2019; 123: e194 - e203.
2. Nickolls SA, Gurrell R, van Amerongen G, et al. Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865. Br J Pharmacol 2018; 175: 708-25.
Subsequent references to Nickolls and colleagues in the text relate to reference 2 above, which is listed as reference 1 in the original article.
The authors and the publisher would like to apologise for any inconvenience caused.